After-hours SMR NuScale Power (NYSE) Q4 26 Feb 2026: ENTRA1 progress in focus
SMR stock trades at $13.43 after hours on 26 Feb 2026, up $0.25 (+1.90%) on volume 24,592,200 as NuScale Power (SMR) posts fourth-quarter results and hosts an earnings call this evening. The report and management commentary will center on ENTRA1 commercialization, project timing and cash needs. Investors should watch near-term revenue guidance, litigation headlines and the company’s path to commercial deployments.
SMR stock: Q4 results and earnings call
NuScale Power Corporation (SMR) reported Q4 and full‑year 2025 results and held its conference call on 26 Feb 2026 after the NYSE close. Management highlighted program milestones but flagged a year‑over‑year revenue step down as construction schedules and partner commitments evolve. The earnings announcement is the immediate catalyst; watch management’s commentary on ENTRA1 module timing and any updated capital‑spend plans. For the market quote and session details see the MarketWatch coverage source.
SMR stock: Financials and valuation metrics
NuScale trades at a market cap of $3.97 billion USD with 133,910,243 shares outstanding and a trailing EPS of -2.14. Price ratios show high future expectations: P/S ~62.07 and P/B ~2.37. Cash per share stands near $4.68, and the current ratio is 1.62, which supports near‑term liquidity. The firm posts negative operating cash flow per share (-1.91) and negative free cash flow per share (-1.91), so valuation relies on successful project conversion and long‑term contract wins.
SMR stock: Key risks—litigation, partner execution and dilution
Risk drivers are clear and specific. Multiple securities class‑action notices reference ENTRA1 disclosures and a reported material expense increase tied to partner arrangements. Management previously disclosed a reported one‑time payment near $495.00 million, which raised questions about partner commitments and cash burn. Insider selling and high institutional ownership (about 78.37%) add volatility. With a 52‑week range of $11.08 to $57.42, execution and litigation headlines can widen price swings quickly.
SMR stock: Catalysts and opportunity set
Positive catalysts include ENTRA1 contract conversion, federal support for advanced nuclear, and commercial interest from data centers and industry. NuScale’s VOYGR modular design targets flexible baseload and process heat markets. Collaborations such as the Oak Ridge National Laboratory AI fuel management work may de‑risk operations and shorten deployment cycles. Sector tailwinds—DOE funding and corporate demand for low‑carbon power—could lift long‑term expectations if NuScale closes firm orders.
SMR stock: Technical snapshot and trading setup
Technically the stock is below its 50‑day average ($17.29) and well below its 200‑day average ($30.83). Momentum indicators show work to do: RSI 38.24, MACD -1.35 with signal -1.09, and ATR 1.48. Day range today was $12.04 to $13.49. Volume of 24,592,200 compared with average volume 26,402,313 signals still‑elevated interest. Short‑term support sits near the year low $11.08; key resistance is the 50‑day near $17.29.
Meyka AI rates SMR with a score out of 100 and forecast
Meyka AI rates SMR with a score out of 100: 72.07 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly $5.83, quarterly $19.28, yearly $41.01, 3‑year $66.97, and 5‑year $92.84. Compared with the current price of $13.43 USD, the model implies a yearly upside of 205.35% and a quarterly upside of 43.56%, while the one‑month projection implies a downside of -56.59%. Forecasts are model‑based projections and not guarantees. For broader market context and analyst notes see MarketBeat coverage source.
Final Thoughts
SMR stock sits at the crossroads of long‑term opportunity and short‑term execution risk. At $13.43 USD after hours on 26 Feb 2026, the market is pricing a significant gap between current financials and NuScale’s ENTRA1 growth thesis. Near term, the earnings call commentary and any updated guidance on module timing, partner commitments and cash needs will drive trading. Our proprietary view incorporates both the upside from successful ENTRA1 commercialization and the downside from litigation and execution slippage. Meyka AI’s forecast model projects a yearly target of $41.01, implying ~205.35% upside from today’s price, but also flags short‑term sensitivity. Investors should weigh project risk, regulatory progress, and cash runway when sizing positions. Meyka AI, an AI‑powered market analysis platform, highlights the stock as a high‑volatility, high‑reward idea for investors with a multi‑year horizon and tolerance for headline risk. Forecasts are model outputs, not investment guarantees.
FAQs
When did NuScale report earnings and how does that affect SMR stock?
NuScale reported Q4 and full‑year 2025 results on 26 Feb 2026 after the NYSE close. The report and the earnings call dictate short‑term SMR stock moves as investors digest guidance, ENTRA1 updates and cash‑flow commentary.
What are the main valuation metrics for SMR stock to watch?
Key metrics include market cap $3.97 billion, EPS -2.14, P/S ~62.07, P/B ~2.37, cash per share $4.68, and negative FCF per share -1.91. These drive relative valuation and sensitivity to contract wins.
What are the biggest risks that could pressure SMR stock?
Primary risks are ENTRA1 execution delays, securities litigation, potential dilution, and higher than expected partner costs. Any material miss on project milestones can widen volatility in SMR stock.
How does Meyka AI view SMR stock and its short‑term forecast?
Meyka AI assigns SMR a B+ (72.07) grade with a BUY suggestion and projects a one‑quarter target of $19.28 and a one‑year target of $41.01. These model outputs are not guarantees and assume successful project progress.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.